The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•11 March 2026•

1 min read

Novo Nordisk Partners with Hims & Hers to Expand GLP-1 Access via Telehealth

Key Facts

1Novo Nordisk partnered with Hims & Hers to expand access to Ozempic and Wegovy via telehealth services.

2The deal aims to shift patients from compounded GLP-1 versions to FDA-approved branded drugs.

Novo Nordisk has announced a strategic partnership with the telehealth platform Hims & Hers Health to distribute its high-demand GLP-1 medications, Ozempic and Wegovy. This collaboration aims to leverage digital health platforms to provide patients with direct access to FDA-approved branded drugs. A primary objective of the deal is to transition consumers away from compounded versions of weight-loss medications produced by various pharmacies. For Novo Nordisk, the move helps protect its brand integrity and market share against non-branded alternatives. Meanwhile, Hims & Hers benefits significantly by securing a reliable supply of authentic GLP-1 treatments for its growing subscriber base. Market analysts view this development as a bullish signal for both companies as they capitalize on the booming demand for weight-loss solutions.